Overall, 108 patients were on active treatment, 31 were receiving steroids, 19 cyclosporine A, 20 complement inhibitors (including 3 cAIHA subjects on C1s inhibitor sutimlimab and 17 C5 inhibitors in PNH), 10 cyclosporine combined with steroids, and 28 a bone marrow stimulating agent including the thrombopoietin receptor agonist (TPO-RA) eltrombopag (in ITP) and recombinant erythropoietin (in LR-MDS). This evidence concerns the gene C1S and myelodysplastic syndrome.